Key Highlights

  • Shares were up 8.30% to USD 3.00 in pre-market trading on November 3, 2026.
  • No company announcement dated October 30 to November 3, 2026 was identified.
  • The company reported crypto holdings valued at about USD 1.06 billion on August 24, 2026.
  • Fiscal 2025 Revenue was USD 35.7 million with an operating loss of USD 154.7 million, per third-party data.
  • The ticker changed from FLGC to ZSTK on January 29, 2026.

What Moved ZeroStack Shares in Pre-Market Trading (up USD 0.2299, 8.30%)?

ZeroStack Corp. (NASDAQ:ZSTK) was up 8.30% to USD 3.00 in pre-market trading on November 3, 2026, measured against the Monday, November 2, 2026 close. Working back from the screen figures, the implied prior close is about USD 2.77 (calculated). A search of company releases and filings found no announcement dated October 30 to November 3, 2026 that explains the gain.

With the price below USD 5, this is a penny stock, and such shares can swing sharply on low Liquidity and carry dilution risk. The move may simply reflect a bounce after the stock closed down 5.12% at USD 2.78 on October 30, 2026, per third-party data.

What Is ZeroStack?

ZeroStack was formerly known as Flora Growth, traded as FLGC, and took the ZSTK ticker on January 29, 2026. Data providers classify it as an asset management company, and it has described a strategy built around digital asset holdings alongside a legacy pharmaceutical distribution Business that includes Phatebo.

On August 18, 2026 it announced completion of its continuance to Texas. The company has roughly 21.8 million shares outstanding, which puts the Market Value near USD 60 million at recent prices, based on third-party data.

What Were the Latest Company Updates?

On August 19, 2026 the company announced a USD 1.0 billion strategic contribution of Memecore tokens at USD 25.19 per share. The stock closed up 169.6% that day, its largest daily move in the period reviewed.

On August 24, 2026 it reported Cryptocurrency holdings with an aggregate market value of about USD 1.06 billion, or about USD 18.19 per partially diluted share. That figure is far above the current share price, but token values can change quickly and the company's disclosures should be read directly. On July 9, 2026 it said it secured purchase orders for up to USD 14.7 million of inventory from two pharmaceutical companies.

What Are the Risks?

Third-party data shows fiscal 2025 revenue of USD 35.7 million, Gross Profit of USD 1.6 million, Operating Cash Flow of negative USD 8.7 million and a current ratio of 1.01. The stock has fallen about 69.9% over the past year.

A Balance Sheet tied to volatile tokens carries valuation, liquidity and accounting risk, and further token or equity financings could dilute holders. Several Schedule 13G filings in September and October 2026 show institutional holders, including one disclosing a stake of 8.3%.

What to Watch Next

The next items to follow are third quarter results, updated disclosure on token holdings and any financing filings. Readers should also watch whether the company issues news that explains recent trading, and whether the pharmaceutical orders convert into reported revenue.